Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-19T15:19:55.895Z Has data issue: false hasContentIssue false

A Clinical Trial with a New Anticonvulsant Drug, α-(P-Aminophenyl)-α-Ethyl Glutarimide Preparation 16038 (Ciba)

Published online by Cambridge University Press:  08 February 2018

Walter Fabisch*
Affiliation:
Mapperley Hospital, Nottingham

Extract

Derivatives of glutarimide are known to exert an effect upon the central nervous system. To name only two which are widely used for clinical purposes: Glutethimide (“Doriden”) is a sedative, Bemigride (“Megimide”) a stimulant. Preparation 16038 (Ciba) α-(p-aminophenyl)-α-ethyl glutarimide, in animal experiments had shown properties which suggested its use as an anticonvulsant, and this paper is an account of a clinical trial with the substance on in- and out-patients suffering from epilepsy.

Type
Original Articles
Copyright
Copyright © Royal College of Psychiatrists, 1959 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Submit a response

eLetters

No eLetters have been published for this article.